Jenny Seligmann, Professor of Gastrointestinal Oncology at University of Leeds, shared a post on LinkedIn:
“Proud to present combined NICHE2 + FOXTROT analysis at ESMO25
In summary
IO superior to chemo (pre or post surgery)
Little role of chemo in dMMR CC (!ATOMIC)
CT staging identified high risk pt
20% recurrence in “good prognosis” pts relevant with effective rx!
Further data to support neoadjuvant IO for routine use! ESP for T4 pts
Privilege to work with super NKI team.”
More insights from Jenny Seligmann.
